ResourceLife Sciences
A flexible approach to neuropharmacology
9 Jan 2023In this application note, QPS describes how it offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
Related Products
Request Quote for All Products
QPS Neuropharmacology Animal Models for Central Nervous System Diseases
QPSThe QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.